Pipeline Overview

We are focused on the development and commercialization of innovative therapeutics for the treatment of cancer.

PreclinicalClinicalMarketed
 IndicationProof of PrincipleSafetyDose OptimizationClinical ActivityPivotalCommercial
Heme Malignancies
CA-4948*
IRAK4
MYD88/TLR-altered NHL

CA-4948*
IRAK4
AML/MDS patients w/ spliceosome mutations

Fimepinostat
HDAC/PI3K
MYC-altered cancers

Immune Checkpoint Inhibitors
CI-8993**
VISTA
VISTA-expressing/ infiltrated Cancers

CA-327*
TIM3/PDL1
TIM3-expressing Cancers

CA-170*
VISTA/PDL1
VISTA-expressing Cancers

Approved Drug
Erivedge***
Hedgehog
Basal Cell Carcinoma

DrugIndicationStage
Heme Malignancies
CA-4948*
IRAK4
MYD88/TLR-altered NHLDose Optimization
CA-4948*
IRAK4
AML/MDS patients w/ spliceosome mutationsSafety
Fimepinostat
HDAC/PI3K
MYC-altered cancersClinical Activity
Immune Checkpoint Inhibitors
CI-8993**
VISTA
VISTA-expressing/ infiltrated CancersSafety
CA-327*
TIM3/PDL1
TIM3-expressing CancersProof of Principle
CA-170*
VISTA/PDL1
VISTA-expressing CancersDose Optimization
Approved Drug
Erivedge***
Hedgehog
Basal Cell CarcinomaCommercial

* IP licensed from Aurigene
** Option to license IP from ImmuNext
*** IP licensed to Genentech (Curis receives royalty income)